ACVR1 and anemia (phenotype): ACVR1/ALK2 inhibitors have been of great interest in the treatment of MF (discussed below) after discovering that momelotinib [28] and, more recently, pacritinib [29] inhibit ACVR1/ALK2 and the hepcidin–ferroportin axis, resulting in notable anemia benefits.